|
|
Support : Dialog Search Aids
: Pharmaprojects Therapeutic Class Codes
Pharmaprojects Therapeutic Class Codes
(DIALOG Files 128*, 928*)
*(Subscriber access.)
 View the PDF version of this document
This list includes the therapeutic categories
in order of their codes. This allows you to
see the hierarchy involved in the classification.
| P |
ANTIPARASITIC PRODUCTS |
| P1A |
AMOEBICIDE
Products that are used in the treatment of amoebiasis (especially by Entamoeba histolytica). |
| P1B |
ANTHELMINTIC
Drugs active against Nemathelminthes (nematodes or roundworms) and Platyhelminthes (flatworms). Products under development include inhibitors of parasitic catalase, glutathione peroxidase and transglutaminase. |
| P1C |
SCHISTOSOMICIDE
Drugs that are active against schistosomiasis (bilharziasis). |
| P1D |
ANTIMALARIAL
Products in development for the treatment of malaria, caused by four species of intracellular Protozoa of the genus Plasmodium, include protozoan electron transport inhibitors and antisense oligonucleotides. For malarial vaccines being developed, see the Vaccine (J7A) section. |
| P1G |
PROTOZOACIDE
Products used for the treatment of the protozoan infections giardiasis, trichomoniasis, trypanosomiasis, leishmaniasis, pneumocystosis and balantidiasis. Compounds in development include inhibitors of ornithine decarboxylase, trypanosomal S-adenosyl-L-methionine decarboxylase and hyperimmune g -globulin antibodies. |
| P1Z |
PARASITICIDE
Antiparasitic drugs that cannot be classified elsewhere in Pharmaprojects including recombinant g -interferon and macrolides isolated from streptomyces sp. |
top
| R |
RESPIRATORY PRODUCTS |
| R3A |
LUNG SURFACTANT
Surfactants are used mainly to treat adult and infant respiratory distress syndrome (hyaline membrane disease) and also, to a lesser degree, emphysema, pneumonia and bronchitis. |
| R4A |
COPD TREATMENT
Chronic obstructive pulmonary disorder (COPD) is an umbrella term covering persistent respiratory diseases characterised by airflow obstruction and loss of expiratory force. The main diseases categorised as COPD are emphysema and chronic bronchitis. Products under investigation include elastase inhibitors, recombinant a 1-antitrypsin, recombinant antileukoproteinases and monocyclic b -lactams that inhibit human PMN elastase. |
| R4B |
CYSTIC FIBROSIS TREATMENT
Cystic fibrosis is a genetic disease of infants, children and young adults, in which there is widespread dysfunction of the exocrine glands. Treatments under investigation include pancreatic enzymes eg human gastric lipase, elastase inhibitors and recombinant versions of the human protein, cystic fibrosis transmembrane regulator (CFTR). |
| R5D |
ANTITUSSIVE
Antitussives are products that relieve or prevent cough, ie cough suppressants. Products being investigated include non-narcotic drugs that act via opiate receptors and catecholamine neurones. |
| R8A |
ANTIASTHMA
Products in development for asthma including allergic/extrinsic and intrinsic/non-atopic asthma. Drugs in development include corticosteroids, mast cell stabilisers eg calmodulin antagonists, histamine H1-receptor antagonists, PAF-antagonists, b 2-agonists, xanthine derivatives, muscarinic M1 and M3 antagonists and inhibitors of the arachidonic acid cascade. |
| R8B |
ANTIALLERGIC, NON-ASTHMA
Preparations that are indicated for rhinitis, sinusitis, catarrh, nasal congestion and similar conditions including sympathomimetics, mast cell stabilisers, antihistamines and IgE related agents. |
| R9A |
RESPIRATORY STIMULANT
Respiratory stimulants increase pulmonary ventilation by their effects on the depth and rate of respiration. |
| R9Z |
RESPIRATORY
Preparations which cannot be classified in any of the other codes in the R section. Products used in the treatment of respiratory distress syndrome (both adult (ARDS) and infant) that are not lung surfactants (R3A). Products in development include prostaglandin E1 (PGE1) agonists, human leucocyte elastase inhibitors, monoclonal antibodies and epidermal growth factor-like factors. |
Last modified on 24 Feb 2012.
top
|
Related Search Aid:
Pharmaprojects (DIALOG Files 128, 928) Major Events in the Update Information (UP) Field
|
Dialog1
Support Home